Abstract
In 14 consecutive patients with recurrent melanoma of the lower limb a total of 35 biopsies were taken at the end of perfusion treatment to assess melphalan tissue concentrations in tumour, skin/subcutis and muscle tissue. In tumour tissue (n = 12) the mean melphalan concentration was 6.8 micrograms g-1, which was significantly higher than that of healthy skin/subcutis (3.2 micrograms g-1; n = 10), but equal to that of muscle tissue (6.5 micrograms g-1; n = 13). The correlation between melphalan concentration in the tissues and the concentration in the perfusate was studied. The latter was assessed in the form of melphalan peak concentration and the area under the curve (AUC0-->60) of the melphalan concentration-time curve. Tumour concentration proved to be correlated linearly with AUC0-->60 (R = 0.6, P = 0.002) and muscle concentration with melphalan peak concentration (R = 0.8, P = 0.04). There was no relation between skin/subcutis concentrations and the perfusate parameters. Further research is warranted to study the relationship between melphalan tissue concentration, tumour response and regional toxicity.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Begleiter A., Froese E. K., Goldenberg G. J. A comparison of melphalan transport in human breast cancer cells and lymphocytes in vitro. Cancer Lett. 1980 Sep;10(3):243–251. doi: 10.1016/0304-3835(80)90077-4. [DOI] [PubMed] [Google Scholar]
- Benckhuijsen C., Kroon B. B., van Geel A. N., Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol. 1988 Apr;14(2):157–163. [PubMed] [Google Scholar]
- Benckhuijsen C., Varossieau F. J., Hart A. A., Wieberdink J., Noordhoek J. Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther. 1986 May;237(2):583–588. [PubMed] [Google Scholar]
- Chang S. Y., Alberts D. S., Farquhar D., Melnick L. R., Walson P. D., Salmon S. E. Hydrolysis and protein binding of melphalan. J Pharm Sci. 1978 May;67(5):682–684. doi: 10.1002/jps.2600670530. [DOI] [PubMed] [Google Scholar]
- Kroon B. B. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol. 1988 Apr;14(2):101–110. [PubMed] [Google Scholar]
- LUCK J. M. Action of p-[di(2-chloroethyl)]-amino-l-phenylalanine on Harding-Passey mouse melanoma. Science. 1956 Jun 1;123(3205):984–985. doi: 10.1126/science.123.3205.984. [DOI] [PubMed] [Google Scholar]
- Parsons P. G., Carter F. B., Morrison L., Regius Mary Sister Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res. 1981 Apr;41(4):1525–1534. [PubMed] [Google Scholar]